Kimberly Clark Report issue

For profit Phase 1 Phase 4
Founded: Neenah WI United States (1872)
Status: No NME R&D (1872)

Organization Overview

First Clinical Trial
2012
NCT02139839
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Kimberly-Clark Corporation

Active Ingredients

Drugs in Phase 4 Trials (1)

estrogen (1 trial)

Drugs in Phase 1 Trials (2)

Lactobacillus acidophilus (1 trial)

sumatriptan (zecuity) (1 trial)

Drugs in Other Trials (5)

Key: Kimberly Clark (0) Acquired (5)

ketorolac (acuvail) (1 trial)

levobupivacaine (chirocaine) (1 trial)

morphine (1 trial)

ropivacaine (naropin) (2 trials)

sodium chloride (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Migraine Disorders (Phase 1)

Nocturia (Phase 4)

Urinary Bladder, Overactive (Phase 4)

Vaginosis, Bacterial (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 8